Clearside Biomedical Inc. is counting on the uveitis indication for its ophthalmic drug Xipere to be enough to keep the company commercially afloat, following the drug's failure in a Phase III study in retinal vein occlusion.
Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat
Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to get through 2020.
More from R&D
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.